Technetium (99mTc) nofetumomab merpentan
 | |
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Clinical data | |
| Trade names | Verluma |
| Pharmacokinetic data | |
| Half-life | 10.5 hours |
| Excretion | renal (64%) |
| Identifiers | |
165942-79-0  | |
| None | |
| Chemical data | |
| (what is this?) (verify) | |
Technetium (99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody used in the diagnosis of lung cancer,[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.[2] The antibody itself, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc).[3]
References
- ↑ Straka, MR; Joyce, JM; Myers, DT (2000). "Tc-99m nofetumomab merpentan complements an equivocal bone scan for detecting skeletal metastatic disease from lung cancer". Clinical nuclear medicine 25 (1): 54–5. doi:10.1097/00003072-200001000-00013. PMID 10634533.
- ↑ Breitz, HB; Tyler, A; Bjorn, MJ; Lesley, T; Weiden, PL (1997). "Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy". Clinical nuclear medicine 22 (9): 615–20. doi:10.1097/00003072-199709000-00007. PMID 9298295.
- ↑ WHO Drug Information